PTC Therapeutics (NASDAQ:PTCT – Get Free Report) and Palatin Technologies (OTCMKTS:PTNT – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.
Earnings and Valuation
This table compares PTC Therapeutics and Palatin Technologies”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PTC Therapeutics | $1.73 billion | 3.37 | $682.64 million | ($0.58) | -120.38 |
| Palatin Technologies | $4.49 million | 0.22 | -$29.74 million | ($60.00) | -0.41 |
Profitability
This table compares PTC Therapeutics and Palatin Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PTC Therapeutics | -3.80% | -362.45% | -1.32% |
| Palatin Technologies | N/A | N/A | -365.57% |
Analyst Ratings
This is a summary of current ratings and price targets for PTC Therapeutics and Palatin Technologies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PTC Therapeutics | 2 | 2 | 9 | 1 | 2.64 |
| Palatin Technologies | 0 | 0 | 0 | 0 | 0.00 |
PTC Therapeutics currently has a consensus price target of $98.55, indicating a potential upside of 41.14%. Given PTC Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than Palatin Technologies.
Institutional and Insider Ownership
11.5% of Palatin Technologies shares are owned by institutional investors. 5.3% of PTC Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Palatin Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
PTC Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Palatin Technologies has a beta of -1.47, suggesting that its stock price is 247% less volatile than the S&P 500.
Summary
PTC Therapeutics beats Palatin Technologies on 10 of the 15 factors compared between the two stocks.
About PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
About Palatin Technologies
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
